Diabetes drug shows promise in reducing risk of cancer

搜索关注在线英语听力室公众号：tingroom，领取免费英语资料大礼包。

　　The research, led by pediatrics professor James Trosko and colleagues from South Korea's Seoul National University, provides biological evidence for previously³ reported epidemiological surveys that long-term use of the drug metformin for Type 2 diabetes reduces the risk of diabetes-associated cancers, such as breast cancers.

　　The research appeared online this week in PLoS One.

　　For the study, Trosko and colleagues focused on the concept that cancers originate from adult human stem cells and that there are many natural and man-made chemicals that enhance the growth of breast cancer cells. Using culture dishes, they grew miniature human breast tumors, or mammospheres, that activated⁵ a certain stem cell gene⁶.

　　Then the mammospheres were exposed to natural estrogen -- a known growth factor and potential breast tumor⁴ promoter -- and man-made chemicals that are known to promote tumors or disrupt the endocrine system.

　　The team found that estrogen and the chemicals caused the mammospheres to increase in numbers and size. However, with metformin added, the numbers and size of the mammospheres were dramatically reduced. While each of the chemicals enhanced growth by different means, metformin seemed to be able to inhibit⁷ their stimulated⁸ growth in all cases.

　　"While future studies are needed to understand the exact mechanism⁹ by which metformin works to reduce the growth of breast cancers, this study reveals the need to determine if the drug might be used as a preventive drug and for individuals who have no indication of any existing cancers," Trosko said.

分享到：